Replies to post #48434 on Biotech Values

[studini]

IDIX
here is the exact report


Company Ticker Brokerage Firm Ratings Change Price Target
Idenix Pharma IDIX Bear Stearns Outperform » Peer Perform

[go seek]

IDIX.. apparently BS was upset on the ITT basis results @ 12 weeks.

the fact that there were no drug drug interaction and response w/ NM283 is dose related (and 200 mg was used here) says there is room for improvement...

most importantly the triple beat the SoC @ all points thru the trial

obviously there is a long way to go... but the pathway for NM283 is clearer today. AND IMO upgrades will follow...